 Michael Clay
Concepts (296)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lipoma | 4 | 2022 | 16 | 1.870 |
Why?
| | Biomarkers, Tumor | 10 | 2024 | 1276 | 1.820 |
Why?
| | Soft Tissue Neoplasms | 5 | 2024 | 115 | 1.260 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 4 | 2024 | 65 | 1.230 |
Why?
| | Liposarcoma | 4 | 2024 | 27 | 1.130 |
Why?
| | Rhabdomyosarcoma | 4 | 2022 | 72 | 1.040 |
Why?
| | Adrenal Cortex Neoplasms | 3 | 2023 | 63 | 1.030 |
Why?
| | In Situ Hybridization, Fluorescence | 5 | 2024 | 317 | 0.950 |
Why?
| | Adrenocortical Carcinoma | 2 | 2023 | 65 | 0.900 |
Why?
| | DNA Methylation | 5 | 2024 | 643 | 0.870 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 2 | 2013 | 56 | 0.800 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2013 | 83 | 0.780 |
Why?
| | Tissue Scaffolds | 1 | 2024 | 211 | 0.760 |
Why?
| | Surgical Wound Infection | 1 | 2024 | 307 | 0.710 |
Why?
| | Immunohistochemistry | 7 | 2024 | 1738 | 0.680 |
Why?
| | Extracellular Matrix | 1 | 2024 | 528 | 0.670 |
Why?
| | Fibroma | 1 | 2020 | 21 | 0.650 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 1396 | 0.620 |
Why?
| | Succinate Dehydrogenase | 1 | 2019 | 50 | 0.610 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2019 | 38 | 0.600 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2019 | 77 | 0.580 |
Why?
| | Breast Neoplasms | 3 | 2014 | 2253 | 0.530 |
Why?
| | Kidney Neoplasms | 4 | 2024 | 403 | 0.520 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2016 | 47 | 0.520 |
Why?
| | Gene Amplification | 2 | 2020 | 104 | 0.510 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1774 | 0.490 |
Why?
| | DNA Mismatch Repair | 1 | 2014 | 49 | 0.450 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 35 | 0.440 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 64 | 0.410 |
Why?
| | Neoplasms, Second Primary | 1 | 2014 | 118 | 0.410 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2023 | 528 | 0.410 |
Why?
| | Diagnosis, Differential | 6 | 2024 | 1483 | 0.410 |
Why?
| | Translocation, Genetic | 1 | 2013 | 105 | 0.400 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 196 | 0.380 |
Why?
| | Wilms Tumor | 3 | 2023 | 86 | 0.370 |
Why?
| | Sexually Transmitted Diseases, Viral | 1 | 2010 | 10 | 0.340 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2011 | 35 | 0.340 |
Why?
| | Myometrium | 1 | 2011 | 39 | 0.340 |
Why?
| | Li-Fraumeni Syndrome | 2 | 2021 | 14 | 0.330 |
Why?
| | Receptor, ErbB-2 | 1 | 2013 | 341 | 0.330 |
Why?
| | Nuclear Proteins | 4 | 2021 | 712 | 0.330 |
Why?
| | Anus Neoplasms | 1 | 2010 | 33 | 0.330 |
Why?
| | Uterine Neoplasms | 1 | 2011 | 109 | 0.320 |
Why?
| | Humans | 43 | 2024 | 137585 | 0.290 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 172 | 0.290 |
Why?
| | Genomics | 3 | 2021 | 795 | 0.260 |
Why?
| | Male | 27 | 2024 | 67762 | 0.260 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1692 | 0.260 |
Why?
| | Female | 26 | 2024 | 73304 | 0.240 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2024 | 215 | 0.230 |
Why?
| | Myoepithelioma | 1 | 2024 | 4 | 0.230 |
Why?
| | Hyphae | 1 | 2024 | 10 | 0.230 |
Why?
| | Neoplasms | 4 | 2021 | 2671 | 0.230 |
Why?
| | Epigenesis, Genetic | 3 | 2024 | 660 | 0.220 |
Why?
| | Child, Preschool | 9 | 2024 | 11074 | 0.220 |
Why?
| | Young Adult | 8 | 2024 | 13209 | 0.220 |
Why?
| | Adamantinoma | 1 | 2023 | 4 | 0.210 |
Why?
| | Oncogene Fusion | 2 | 2020 | 13 | 0.210 |
Why?
| | Fungi | 1 | 2024 | 144 | 0.200 |
Why?
| | Antineoplastic Agents | 3 | 2023 | 2129 | 0.200 |
Why?
| | Adult | 15 | 2024 | 37929 | 0.200 |
Why?
| | X-linked Nuclear Protein | 2 | 2020 | 9 | 0.200 |
Why?
| | Meniscus | 1 | 2023 | 22 | 0.200 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2022 | 22 | 0.190 |
Why?
| | Child | 15 | 2024 | 21935 | 0.190 |
Why?
| | Liver Neoplasms | 2 | 2019 | 786 | 0.190 |
Why?
| | Wound Healing | 1 | 2024 | 331 | 0.180 |
Why?
| | Infant | 10 | 2021 | 9465 | 0.180 |
Why?
| | Neuroblastoma | 2 | 2020 | 160 | 0.180 |
Why?
| | Aged, 80 and over | 5 | 2024 | 7635 | 0.180 |
Why?
| | Penetrance | 1 | 2021 | 28 | 0.180 |
Why?
| | In Situ Hybridization | 1 | 2021 | 316 | 0.180 |
Why?
| | Immunoglobulin A | 1 | 2022 | 211 | 0.180 |
Why?
| | Middle Aged | 11 | 2024 | 33479 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2023 | 247 | 0.170 |
Why?
| | Orthopedic Procedures | 1 | 2023 | 216 | 0.170 |
Why?
| | Mutation | 4 | 2021 | 3958 | 0.170 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2023 | 159 | 0.170 |
Why?
| | Adolescent | 9 | 2024 | 21513 | 0.170 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 872 | 0.170 |
Why?
| | Myofibroma | 1 | 2020 | 4 | 0.170 |
Why?
| | Whole Genome Sequencing | 1 | 2021 | 160 | 0.170 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 182 | 0.170 |
Why?
| | Germ Cells | 1 | 2021 | 64 | 0.170 |
Why?
| | Xanthogranuloma, Juvenile | 1 | 2020 | 6 | 0.170 |
Why?
| | Aged | 8 | 2024 | 23961 | 0.170 |
Why?
| | Tandem Repeat Sequences | 2 | 2017 | 21 | 0.170 |
Why?
| | Introns | 1 | 2021 | 258 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 1079 | 0.170 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 29 | 0.170 |
Why?
| | Exons | 1 | 2021 | 355 | 0.170 |
Why?
| | Receptor, trkA | 1 | 2020 | 18 | 0.170 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2020 | 48 | 0.170 |
Why?
| | N-Myc Proto-Oncogene Protein | 1 | 2020 | 9 | 0.170 |
Why?
| | Phthalazines | 1 | 2020 | 45 | 0.160 |
Why?
| | Sarcoma, Ewing | 1 | 2021 | 97 | 0.160 |
Why?
| | Osteoarthritis, Knee | 1 | 2023 | 254 | 0.160 |
Why?
| | Computational Biology | 2 | 2021 | 644 | 0.160 |
Why?
| | Lamin Type A | 1 | 2020 | 49 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.160 |
Why?
| | Cell Nucleus | 2 | 2020 | 620 | 0.160 |
Why?
| | Clonal Evolution | 1 | 2019 | 45 | 0.160 |
Why?
| | Narcotics | 1 | 2019 | 52 | 0.160 |
Why?
| | Cell Dedifferentiation | 1 | 2019 | 32 | 0.160 |
Why?
| | Phenotype | 2 | 2020 | 3196 | 0.160 |
Why?
| | Office Visits | 1 | 2019 | 93 | 0.150 |
Why?
| | Mutation, Missense | 1 | 2021 | 341 | 0.150 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 115 | 0.150 |
Why?
| | Muscle Neoplasms | 1 | 2018 | 8 | 0.150 |
Why?
| | Psychomotor Disorders | 1 | 2018 | 13 | 0.150 |
Why?
| | DNA Damage | 1 | 2021 | 420 | 0.150 |
Why?
| | Patella | 1 | 2018 | 26 | 0.150 |
Why?
| | Scrotum | 1 | 2018 | 27 | 0.150 |
Why?
| | Rhabdoid Tumor | 1 | 2019 | 99 | 0.150 |
Why?
| | Codon, Nonsense | 1 | 2018 | 44 | 0.140 |
Why?
| | Neuroendocrine Tumors | 1 | 2019 | 116 | 0.140 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2018 | 434 | 0.140 |
Why?
| | ErbB Receptors | 2 | 2022 | 614 | 0.140 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2023 | 363 | 0.140 |
Why?
| | Craniofacial Abnormalities | 1 | 2018 | 72 | 0.140 |
Why?
| | Immunophenotyping | 1 | 2019 | 318 | 0.140 |
Why?
| | Prognosis | 3 | 2022 | 4030 | 0.140 |
Why?
| | Tumor Burden | 2 | 2017 | 309 | 0.140 |
Why?
| | Health Expenditures | 1 | 2019 | 189 | 0.140 |
Why?
| | Histone Acetyltransferases | 1 | 2018 | 60 | 0.140 |
Why?
| | Urogenital Abnormalities | 1 | 2018 | 64 | 0.140 |
Why?
| | Mice | 8 | 2022 | 17787 | 0.140 |
Why?
| | Fused Kidney | 1 | 2017 | 1 | 0.140 |
Why?
| | Heterozygote | 1 | 2018 | 293 | 0.140 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 617 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2019 | 245 | 0.140 |
Why?
| | Opiate Substitution Treatment | 1 | 2019 | 155 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 8 | 0.140 |
Why?
| | Sarcoma, Clear Cell | 1 | 2017 | 10 | 0.140 |
Why?
| | Fibrosarcoma | 1 | 2017 | 22 | 0.130 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 313 | 0.130 |
Why?
| | Insurance, Health | 1 | 2019 | 283 | 0.130 |
Why?
| | Beckwith-Wiedemann Syndrome | 1 | 2016 | 6 | 0.130 |
Why?
| | Intellectual Disability | 1 | 2018 | 165 | 0.130 |
Why?
| | Hemangioendothelioma | 1 | 2016 | 15 | 0.130 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2016 | 8 | 0.130 |
Why?
| | Retrospective Studies | 6 | 2024 | 15657 | 0.130 |
Why?
| | Ectodermal Dysplasia | 1 | 2016 | 19 | 0.130 |
Why?
| | Genetic Variation | 1 | 2021 | 991 | 0.130 |
Why?
| | Scalp | 1 | 2016 | 35 | 0.130 |
Why?
| | Reproducibility of Results | 2 | 2015 | 3284 | 0.120 |
Why?
| | Troponin | 1 | 2015 | 50 | 0.120 |
Why?
| | Buprenorphine | 1 | 2019 | 173 | 0.120 |
Why?
| | Sarcoma, Kaposi | 1 | 2016 | 81 | 0.120 |
Why?
| | Mismatch Repair Endonuclease PMS2 | 1 | 2014 | 4 | 0.120 |
Why?
| | MutL Protein Homolog 1 | 1 | 2014 | 12 | 0.120 |
Why?
| | MutS Homolog 2 Protein | 1 | 2014 | 15 | 0.110 |
Why?
| | Clone Cells | 2 | 2017 | 265 | 0.110 |
Why?
| | DNA Repair Enzymes | 1 | 2014 | 28 | 0.110 |
Why?
| | Chromosome Aberrations | 2 | 2017 | 156 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2019 | 801 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2426 | 0.110 |
Why?
| | Adenosine Triphosphatases | 1 | 2014 | 168 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2031 | 0.100 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 399 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1167 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2017 | 427 | 0.100 |
Why?
| | Proto-Oncogene Proteins | 1 | 2017 | 648 | 0.100 |
Why?
| | Breast | 1 | 2013 | 151 | 0.100 |
Why?
| | Trastuzumab | 1 | 2013 | 96 | 0.100 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2014 | 224 | 0.100 |
Why?
| | Algorithms | 1 | 2020 | 1704 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 804 | 0.090 |
Why?
| | Mastectomy | 1 | 2013 | 137 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1946 | 0.090 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 515 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2014 | 430 | 0.090 |
Why?
| | Disease Management | 1 | 2015 | 628 | 0.090 |
Why?
| | Epithelioid Cells | 1 | 2011 | 9 | 0.090 |
Why?
| | Genomic Imprinting | 2 | 2023 | 26 | 0.090 |
Why?
| | Risk Factors | 2 | 2015 | 10388 | 0.090 |
Why?
| | Penile Neoplasms | 1 | 2010 | 7 | 0.090 |
Why?
| | Kidney | 1 | 2018 | 1468 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4295 | 0.080 |
Why?
| | Animals | 10 | 2023 | 36940 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1238 | 0.080 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2010 | 42 | 0.080 |
Why?
| | DNA, Neoplasm | 1 | 2010 | 164 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1236 | 0.080 |
Why?
| | Papillomaviridae | 1 | 2010 | 125 | 0.080 |
Why?
| | Critical Illness | 1 | 2015 | 811 | 0.080 |
Why?
| | Mice, Nude | 2 | 2021 | 698 | 0.080 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1389 | 0.070 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 452 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2691 | 0.070 |
Why?
| | Liver | 1 | 2016 | 1943 | 0.070 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2010 | 257 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1502 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1357 | 0.070 |
Why?
| | Rodent Control | 1 | 1985 | 2 | 0.060 |
Why?
| | Leptospira interrogans | 1 | 1985 | 4 | 0.060 |
Why?
| | DNA | 2 | 2023 | 1459 | 0.060 |
Why?
| | Leptospirosis | 1 | 1985 | 8 | 0.060 |
Why?
| | Gene Fusion | 1 | 2024 | 27 | 0.060 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 683 | 0.060 |
Why?
| | Diaphyses | 1 | 2023 | 13 | 0.050 |
Why?
| | Ulna | 1 | 2023 | 27 | 0.050 |
Why?
| | Occupational Diseases | 1 | 1985 | 156 | 0.050 |
Why?
| | Activating Transcription Factor 4 | 1 | 2023 | 20 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2023 | 46 | 0.050 |
Why?
| | Fibula | 1 | 2023 | 43 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2010 | 940 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2023 | 156 | 0.050 |
Why?
| | Prospective Studies | 1 | 2014 | 7604 | 0.050 |
Why?
| | Drug Resistance | 1 | 2022 | 169 | 0.050 |
Why?
| | Carcinoma, Renal Cell | 1 | 2024 | 217 | 0.050 |
Why?
| | Muscle Development | 1 | 2022 | 111 | 0.040 |
Why?
| | Cellular Senescence | 1 | 2023 | 189 | 0.040 |
Why?
| | Gene Knock-In Techniques | 1 | 2021 | 56 | 0.040 |
Why?
| | Myositis Ossificans | 1 | 2020 | 4 | 0.040 |
Why?
| | Periosteum | 1 | 2020 | 12 | 0.040 |
Why?
| | Fasciitis | 1 | 2020 | 12 | 0.040 |
Why?
| | Brazil | 1 | 2021 | 167 | 0.040 |
Why?
| | Biopsy | 1 | 2024 | 1129 | 0.040 |
Why?
| | Dasatinib | 1 | 2020 | 54 | 0.040 |
Why?
| | Freezing | 1 | 2020 | 90 | 0.040 |
Why?
| | Complement Activation | 1 | 2023 | 415 | 0.040 |
Why?
| | Autoantigens | 1 | 2022 | 430 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2020 | 150 | 0.040 |
Why?
| | Etoposide | 1 | 2019 | 158 | 0.040 |
Why?
| | Carboplatin | 1 | 2019 | 144 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2020 | 216 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 2019 | 78 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 674 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 307 | 0.040 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2018 | 44 | 0.040 |
Why?
| | Genotype | 1 | 2023 | 1916 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2018 | 59 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 955 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2022 | 893 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2017 | 4 | 0.040 |
Why?
| | Epigenomics | 1 | 2018 | 115 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 6079 | 0.030 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2017 | 59 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 500 | 0.030 |
Why?
| | Bortezomib | 1 | 2017 | 54 | 0.030 |
Why?
| | Genes, p53 | 1 | 2017 | 72 | 0.030 |
Why?
| | Signal Transduction | 2 | 2023 | 5079 | 0.030 |
Why?
| | Cohort Studies | 2 | 2020 | 5742 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2017 | 89 | 0.030 |
Why?
| | Vincristine | 1 | 2017 | 116 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 138 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2020 | 622 | 0.030 |
Why?
| | Camptothecin | 1 | 2017 | 116 | 0.030 |
Why?
| | Pyrimidinones | 1 | 2017 | 113 | 0.030 |
Why?
| | Stromal Cells | 1 | 2016 | 112 | 0.030 |
Why?
| | High-Throughput Screening Assays | 1 | 2017 | 158 | 0.030 |
Why?
| | Family | 1 | 2020 | 671 | 0.030 |
Why?
| | Fibroblasts | 1 | 2021 | 996 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2167 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1430 | 0.030 |
Why?
| | beta Catenin | 1 | 2017 | 253 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 411 | 0.030 |
Why?
| | Medicaid | 1 | 2019 | 435 | 0.030 |
Why?
| | Autoantibodies | 1 | 2022 | 1496 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1066 | 0.030 |
Why?
| | Leukocyte Transfusion | 1 | 1994 | 2 | 0.030 |
Why?
| | Precision Medicine | 1 | 2018 | 429 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2553 | 0.030 |
Why?
| | Indoles | 1 | 2017 | 412 | 0.030 |
Why?
| | Granulocytes | 1 | 1994 | 80 | 0.030 |
Why?
| | Pyrazoles | 1 | 2017 | 423 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 470 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2017 | 1062 | 0.030 |
Why?
| | Medicare | 1 | 2019 | 773 | 0.030 |
Why?
| | Mycoses | 1 | 1994 | 79 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 948 | 0.030 |
Why?
| | Neutropenia | 1 | 1994 | 146 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 4193 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2020 | 3015 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2019 | 654 | 0.020 |
Why?
| | Aging | 1 | 2023 | 1864 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 1994 | 286 | 0.020 |
Why?
| | Acute Coronary Syndrome | 1 | 2015 | 279 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 1111 | 0.020 |
Why?
| | United States Department of Veterans Affairs | 1 | 2015 | 678 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 445 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2015 | 911 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 3412 | 0.020 |
Why?
| | United States | 2 | 2019 | 14841 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5757 | 0.020 |
Why?
| | Registries | 1 | 2017 | 2035 | 0.020 |
Why?
| | Michigan | 1 | 1985 | 109 | 0.010 |
Why?
| | Epidemiologic Methods | 1 | 1985 | 97 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2019 | 10811 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 4149 | 0.010 |
Why?
| | Rats | 1 | 1985 | 5647 | 0.010 |
Why?
| | Aspergillus | 1 | 1994 | 17 | 0.010 |
Why?
| | Candida albicans | 1 | 1994 | 54 | 0.010 |
Why?
| | Candidiasis | 1 | 1994 | 56 | 0.010 |
Why?
|
|
Clay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|